Floatz Rating
CCC51/100
Confidence
Indicative
Sponsor
Gilead Sciences
Modality
Small molecule
Development Phase
Phase 2
Status
Dormant
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
36Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT02943447CT.gov Study to Evaluate the Safety, Tolerability, and Efficacy of Cilofexor in Adults With Primary Biliary Cholangitis Without Cirrhosis | — | Terminated | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
89High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Primary Biliary Cholangitis
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Cilofexor (this asset) | Gilead Sciences | P2 | CCC · 51 |
| Ursodeoxycholic Acid | Xijing Hospital of Digestive Diseases | P4 | A |
| Fenofibrate | Xijing Hospital of Digestive Diseases | P3 | BB |
| Saroglitazar | Zydus Therapeutics Inc. | P3 | BB |
| cs0159 | Cascade Pharmaceuticals, Inc | P3 | BB |
| Obeticholic Acid | Intercept Pharmaceuticals | P3 | BB |
| Seladelpar | Gilead Sciences | P3 | BB |
| 2-(P-(2-(P-CHLOROBENZAMIDO)ETHYL)PHENOXY)-2-METHYLPROPIONIC ACID | Intercept Pharmaceuticals | P3 | BB |
| Abatacept Recombinant | Christopher Bowlus, MD | P4 | BB |
+41 more in the Primary Biliary Cholangitis cohort
Other indications for Cilofexor
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Metabolic Dysfunction-Associated Steatohepatitis | — | P2 | B · 63 |
| Primary Sclerosing Cholangitis | — | P3 | B · 59 |
| Metabolic Dysfunction-Associated Steatotic Liver Disease | — | P2 | CCC · 53 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Cilofexor in Primary Biliary Cholangitis. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/cilofexor-primary-biliary-cholangitis
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →